Steroid-Sparing Agents

Cross-source consensus on Steroid-Sparing Agents from 1 sources and 4 claims.

1 sources · 4 claims

Risks & contraindications

Relapse occurs in 75% of patients after cyclosporine withdrawal and in over 90% after mycophenolate mofetil withdrawal. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
No consensus exists for optimal management of frequently relapsing or steroid-dependent nephrotic syndrome. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
IPNA guidelines list potential oral steroid-sparing agents without specifying a preference among them. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
Cyclophosphamide achieves a sustained remission rate of 42% at 2 years but is limited by significant side effects. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial